Cancerous Inhibitor of PP2A Silencing Inhibits Proliferation and Promotes Apoptosis in Human Multiple Myeloma Cells

Figure 6

IGF-1 treatment reverses the effects of CIP2A knockdown in RPMI-8226 and NCI-H929 cells. ((a) and (b)) RPMI-8226 (a) and NCI-H929 (b) cells transfected with si-CIP2A were treated with PBS (control) or the PI3K activator IGF-1, and the effect on cell viability was determined by the MTS assay. The results were normalized to si-Scr transfected cells. ((c) and (d)) Effect of IGF-1 treatment on RPMI-8226 and NCI-H929 cell apoptosis. Flow cytometry scatterplot of apoptotic RPMI-8226 and NCI-H929 cells labeled with fluorescein isothiocyanate (FITC) and propidium iodide and sorted 72 h after transfection with si-CIP2A followed by treatment with PBS or IGF-1 (c) and quantitative analysis of early apoptotic cells after transfection with si-CIP2A followed by treatment with PBS or IGF-1 (d). (e) The cleavage of PARP in each group detected by western blot. CF: cleaved fragment. Data are expressed as mean ± SD of three independent experiments. < 0.05.

(a)

(b)

(c)

(d)

(e)